|Videos|January 16, 2015
Predictive Value of Diagnostic Tests
Advertisement
Bryan Loy, MD, describes how diagnostic test results can be of help to providers when having conversations with their patients about treatments. Providing patients with a more specific concept of response and recurrence, such as percentages or odds, can help patients understand their options.
Advertisement
Related to this article
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
3
How ID, HIV Clinicians Can Influence Policy in an Election Year
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5